The Multicomponent Improvement” (MCI) endpoint is a composite endpoint measuring improvement in 6-minute walk distance, reduction or maintenance of low N-terminal pro-BNP levels, and improvement or maintenance of WHO functional class I or II.
The American Journal of Respiratory and Critical Care Medicine has published the abstract of a session at the American Thoracic Society Congress 2024 analysing the MCI endpoint in patients with pulmonary arterial hypertension treated with sotatercept. The analysis supports the MCI as a clinically meaningful composite endpoint.
The PDF of this study is available at this link on the Official Publications of the American Thoracic Society
Citation
A.B. Waxman, D.B. Badesch, J.S.R. Gibbs, H.A. Ardeschir Ghofrani, M. Gomberg-Maitland, M.J.C. Humbert, V.V. Mclaughlin, I.R. Preston, Rogerio Souza, @E. Grünig, G. Kopeć, G.M. Bohns Meyer, K.M. Olsson, S. Rosenkranz, Y. Zhao, A. Lau, A.G. Cornell, J. Pena, and M.M. Hoeper. Prognostic Value of the Multicomponent Improvement (MCI) Endpoint in Patients With Pulmonary Arterial Hypertension (PAH) Treated With Sota